Press releases

REPRISE II data honored as Best Abstract 2013 at PCR London valves course

Represents significant milestone toward obtaining additional key regulatory approvals for the SYNERGY™ Stent System.

Unlike medications alone, bronchial thermoplasty provides benefits that last for years rather than hours

Boston Scientific will participate in the healthcare conference on September 11 in Boston. Learn how to watch the webcast or replay.

Boston Scientific will participate in the healthcare conference on September 9 in New York. Learn how to watch the webcast or replay.

First implantations in Zhejiang province and Beijing mark the launch of the COGNIS CRT-D in the Chinese market.

Products join the company's growing portfolio of next generation EP tools designed to redefine ablation technology.

Innovative bare metal stent designed to treat Peripheral Artery Disease.

Public offering consists of $600 million of 2.650% notes due October 1, 2018 and $450 million of 4.125% notes due October 1, 2023.

Company expects to receive the net offering proceeds upon closing on August 13, 2013, subject to customary closing conditions.